Pharma BD Deal Intelligence
One durable winner (Creon), one patent-cliff casualty (TriCor/Trilipix), and a decade of antitrust litigation on AndroGel that was ultimately reversed but never turned into upside.
Full analysis, sources & comparables →Total consideration €5.2B (€4.5B upfront cash + up to €300M milestones 2011-2013 + ~€400M assumed liabilities); expected to add $0.10 EPS in 2010, increasing…
Abbott CEO Miles White: 'The acquisition of Solvay Pharmaceuticals is a key part of Abbott's strategy to bolster our presence in key markets and deliver…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Abbott completed acquisition of Solvay's pharmaceuticals unit for $6.2B (€4.5B), expanding emerging markets and pharmaceutical product portfolio. Deal originally announced 2009, closed February 2010.
One durable winner (Creon), one patent-cliff casualty (TriCor/Trilipix), and a decade of antitrust litigation on AndroGel that was ultimately reversed but never turned into upside.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Abbott Laboratories / Solvay Pharmaceuticals (this deal) | 2010 | $6.2B | 54 |
| Abbott Laboratories / Knoll Pharmaceutical Company (BASF Pharma) | 2001 | $6.9B | 100 |
| Abbott Laboratories / Knoll Pharmaceuticals (BASF Pharma) | 2000 | $6.9B | 95 |
| Abbott Laboratories / Alere Inc. | 2016 | $5.8B | 95 |
| Abbott Laboratories / St. Jude Medical | 2016 | $30.5B | 82 |
| Abbott Laboratories / TheraSense Inc. | 2004 | $1.2B | 81 |
| Abbott Laboratories / Vysis Inc. | 2001 | $355M | 79 |
← Browse all deals · How we score deals
More: 2010 deals · Abbott Laboratories deals · Gastroenterology deals